S-1: Aspire Biopharma Faces Delisting Amidst Mounting Losses

Aspire Biopharma Holdings, Inc. reports significant net losses and going concern doubt, while facing Nasdaq delisting and substantial shareholder dilution from recent financing activities.

Summary

• Aspire Biopharma Holdings, Inc. (ASBP) is an early-stage biopharmaceutical and supplements company focused on novel sublingual delivery mechanisms.
• The company completed a reverse acquisition on February 17, 2025, with PowerUp Acquisition Corp. becoming Aspire Biopharma Holdings, Inc.
• Aspire reported a net loss of $19,773,114 for the nine months ended September 30, 2025, a significant increase from $544,162 for the same period in 2024.
• General and administrative expenses surged to $15,982,233 for the nine months ended September 30, 2025, primarily due to $14.1 million in stock-based compensation.
• Research and development expenses increased to $823,879 and sales and marketing expenses rose to $696,639 for the nine months ended September 30, 2025.
• The company generated initial revenue of $1,941 from nutraceutical products in the third quarter of 2025.
• Aspire received notices from Nasdaq on April 16, 2025, for failing to meet the minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share) requirements.
• A delisting notice was received on October 15, 2025, and the company has requested a hearing with the Nasdaq Hearings Panel.
• Clinical trials for its high-dose sublingual aspirin product concluded in July 2025, with positive results showing faster bioavailability and quicker anti-coagulant properties compared to oral aspirin.
• Aspire plans to submit a section 505(b)(2) New Drug Application (NDA) for its high-dose aspirin product in 2026, following a pre-IND meeting with the FDA expected in early January 2026.
• The company has developed formulations for sublingual melatonin, vitamins D, E, K, ED medication, and caffeine products, with caffeine products (Buzz Bomb) launched for online sales in August 2025.
• Aspire entered into a Second Equity Line of Credit (ELOC) Agreement with Arena Business Solutions Global SPC II, Ltd. on November 11, 2025, allowing it to sell up to $100,000,000 in common stock to Arena.
• The company issued senior secured convertible debentures for $3,750,000 (20% OID) in February 2025 and convertible notes for $9,687,500 (20% OID) in August 2025.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• As of December 1, 2025, the closing sale price of common stock was $0.099 per share, and warrants were $0.0226 per warrant.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with substantial net losses, a significant accumulated deficit, and explicit going concern doubt. The Nasdaq delisting threat is imminent, and while product development shows some promise, the financial and operational risks are overwhelming, indicating a very challenging outlook.

Positives

• Clinical trials for the high-dose sublingual aspirin product yielded positive results, demonstrating faster aspirin bioavailability and quicker anti-coagulant effects compared to standard oral aspirin, with no adverse reactions.
• The company has developed working formulations for several other sublingual products, including melatonin, vitamins D, E, K, and ED medication, diversifying its product pipeline.
• Caffeine products under the 'Buzz Bomb' brand have been launched for online sales in August 2025, marking the company's first revenue-generating operations.
• A Second ELOC Agreement provides the company with the right to raise up to $100,000,000 in capital through common stock sales to Arena, offering a potential source of future funding.
• Aspire has retained experienced counsel to assist with FDA approval processes, including seeking fast-track approval for its sublingual aspirin product under 505(b)(2).

Negatives

• The company reported a significant net loss of $19,773,114 for the nine months ended September 30, 2025, a substantial increase from the prior year.
• Aspire has an accumulated deficit of $22,550,347 and a working capital deficit of $11,457,377 as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• The company received delisting notices from Nasdaq for failing to meet the minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share) requirements, with its stock trading at $0.099 per share as of December 1, 2025.
• Significant shareholder dilution has occurred and is expected to continue from the conversion of convertible notes and potential sales under the ELOC Agreement.
• Several previously acquired intellectual property assets, including patent applications and the 'Instaprin' trademark, have expired or been cancelled, though new applications have been filed.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to additional material misstatements if not remediated.
• Aspire has a limited operating history and has incurred net losses every year since its inception, with no assurance of future profitability.

Risks

• Aspire has a limited operating history and has incurred net losses in every year since its inception, with no assurance of achieving profitability.
• The company will require substantial additional financing to achieve its goals, and failure to obtain necessary capital could force delays or termination of product development or commercialization efforts.
• If Aspire does not adequately protect its intellectual property rights, it may experience a loss of revenue and its operations and growth prospects may be materially harmed.
• The market price of common stock may be volatile and fluctuate substantially, which could cause the value of investment to decline.
• If Aspire fails to meet the continued listing standards of Nasdaq, its common stock may be delisted, which could adversely affect liquidity and market price.
• Management has identified material weaknesses in internal control over financial reporting, which could result in additional material misstatements if not remediated.
• The technology platforms and product candidates are based on novel technologies, and the regulatory approval pathway for sublingual aspirin is unproven, potentially never leading to marketable products.
• Aspire's business is highly dependent on the success of its lead product candidate, high-dose sublingual aspirin, which requires significant additional clinical testing before regulatory approval.
• Clinical development involves a lengthy and expensive process with uncertain outcomes, and earlier study results may not be predictive of future clinical trial results.
• Product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Reliance on third parties to conduct clinical trials and manufacture product supplies poses risks if they fail to carry out contractual duties or meet deadlines.
• Failure to develop additional product candidates would limit commercial opportunity.
• The company faces significant competition from other biotechnology and pharmaceutical companies with substantially greater resources.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of product candidates.
• The sale by Arena of a significant number of Selling Shareholder Shares could cause the market price of common stock to decline and be highly volatile, resulting in substantial dilution to other shareholders.

Future Outlook

Aspire Biopharma intends to submit a section 505(b)(2) NDA for its high-dose sublingual aspirin product in 2026, following a pre-IND meeting with the FDA. The company expects to generate revenue through developing and marketing drugs and nutraceuticals using its sublingual delivery technology, and may enter into license or collaboration agreements. It plans to build a focused sales and marketing organization in the United States for its aspirin products, and seek third-party distribution internationally. The company anticipates increased general and administrative, research and development, and sales and marketing expenses commensurate with business growth and public company status. Aspire will need to raise additional financing through equity or debt offerings to fund its operations and development goals.

Management Comments

• Management believes that the positive results from the aspirin clinical trials (faster bioavailability and more significant impact on TxB2) are very positive.
• Management believes that the novel use of aspirin and its claims will be beneficial for patients needing faster delivery and gastric tract avoidance, and that the FDA would consider and welcome a filing supporting this novel mode of administration.
• Management believes that Glatt is capable of producing the aspirin drug product to support the development plan, but their current capacity may be insufficient for planned commercial needs, potentially requiring additional or alternative third-party manufacturers.
• Management believes that both Glatt and the fill-and-finish contract manufacturer are compliant under current good manufacturing practice (cGMP) requirements and have experience with cGMP inspections.
• Management believes that the company's sublingual absorption technology, knowledge, experience, and scientific resources provide competitive advantages.
• Management believes that it will be possible to access the heart attack and stroke prevention market through a targeted hospital and/or specialty care sales force.
• Management believes that while previously acquired intellectual property is dead or expired, Aspire has used these technologies and relationships as the foundation of their new patent applications and formulations.

Industry Context

Aspire Biopharma operates in the highly competitive biopharmaceutical and supplements industries, characterized by rapidly advancing technologies and a strong emphasis on proprietary products. The company aims to disrupt the market with novel sublingual delivery mechanisms for known drugs like aspirin, targeting conditions such as heart attacks and strokes, and potentially addressing the opioid crisis with high-dose aspirin for pain management. While there are no current sublingual aspirin products on the market, Aspire will compete with established oral aspirin products (e.g., Bayer, Advil, Tylenol) and other therapies under development. Its nutraceutical products, like the Buzz Bomb caffeine supplement, enter a crowded but growing market for health and wellness supplements. The company's strategy of seeking 505(b)(2) FDA approval leverages existing safety data for aspirin, potentially expediting market entry compared to entirely new chemical entities.

Comparison to Industry Standards

• Aspire's sublingual aspirin product demonstrated faster bioavailability and quicker anti-coagulant properties compared to standard oral aspirin tablets in clinical trials, suggesting a potential advantage in emergency situations like acute myocardial infarction where rapid action is critical. This differentiates it from existing oral aspirin products like Bayer aspirin, Advil, and Tylenol.
• The company's pursuit of 505(b)(2) FDA approval for its high-dose aspirin product leverages the extensive safety history of aspirin (over 100 years), which is a common strategy for drug developers to expedite approval for new formulations or uses of existing drugs, rather than undergoing full 505(b)(1) new chemical entity development.
• Aspire's reliance on third-party contract manufacturers for cGMP production of its product candidates is a standard industry practice for early-stage biopharmaceutical companies that do not own their manufacturing facilities, similar to many small and mid-cap biotech firms.
• The company's initial revenue generation from nutraceutical products like 'Buzz Bomb' caffeine supplements positions it in a market with numerous competitors, including established supplement brands and energy drink companies, where product differentiation, marketing, and distribution are key to success.
• Aspire's current financial state, characterized by significant net losses, an accumulated deficit, and going concern doubt, is not uncommon for early-stage biopharmaceutical companies engaged in extensive R&D, but the magnitude of the losses and the Nasdaq delisting risk are severe compared to industry peers with more stable financial footing or clearer paths to commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• Instaprin Pharmaceuticals' former Chief Executive Officer, Donald A. Milne III, was convicted on a conspiracy to commit securities fraud charge, having diverted significant funds for personal use.
• The company acquired Instaprin Pharmaceuticals' assets, but the former CEO is not affiliated with Aspire, and all shares held by him were distributed to Instaprin shareholders in partial satisfaction of an SEC judgment.
• There is a risk of reputational harm if Aspire chooses to use the 'Instaprin' trademark due to its association with the former CEO's fraudulent activities.

Related Party Transactions

• The company assumed $499,214 in liabilities related to working capital loans from the New Sponsor and its affiliates (SSVK Associates, LLC, Apogee Pharma, Jinal Sheth, Apogee Pharma 2) on February 17, 2025.
• At the close of the Reverse Acquisition, Apogee Pharma was issued 50,000 Class A Common Stock as commitment fees.
• The company assumed $1,500,000 of debt under First and Second Subscription Agreements with the New Sponsor and its affiliate VKSS Capital, LLC, as of February 17, 2025.
• At the close of the Reverse Acquisition, 1,750,000 commitment fee shares were transferred to investors under these subscription agreements.
• The company assumed $353,679 of liabilities due to the Sponsor of PowerUp related to administrative services fees and a residual balance from IPO proceeds as of February 17, 2025.
• A modified promissory note fee of $1,000,000 is still outstanding and payable to the Sponsor as of September 30, 2025.
• Aspire Biopharma, Inc. incurred expenses totaling $356,032 and $100,000 in 2024 and 2023, respectively, to officers and directors for compensation.
• The company intermittently rents corporate office space on a month-to-month basis from an officer and director.
• Non-convertible 20% OID notes payable to related parties totaling $885,564 were outstanding as of September 30, 2025, formalized from working capital advances.
• The Securities Purchase Agreement on February 17, 2025, involved Cobra Alternative Capital Strategies, LLC, an entity controlled by Aspire's former Director of Investor Relations, Lance Friedman, and Target Capital X LLC.

Stakeholder Impact

• Shareholders face significant dilution from the potential sale of up to 41,500,000 shares by the Selling Shareholder and the conversion of existing convertible notes.
• Existing shareholders' investment value is at high risk due to the company's substantial net losses, accumulated deficit, and going concern doubt.
• The potential delisting from Nasdaq could severely impact the liquidity and market price of the common stock and warrants, making it difficult for shareholders to trade their securities.
• Employees and management face uncertainty due to the company's financial instability and the ongoing search for a permanent CEO.
• Creditors, particularly holders of the secured convertible debentures and notes, are exposed to the risk of default given the company's liquidity challenges and going concern warning.
• Customers of the company's nascent nutraceutical products may face supply chain disruptions or product availability issues if the company's financial condition deteriorates further.
• Suppliers and contract manufacturers face payment risks if the company is unable to secure adequate additional financing.

Next Steps

• Receive a written response from the FDA regarding the pre-IND meeting for the high-dose sublingual aspirin product (expected first week of January 2026).
• Submit a section 505(b)(2) New Drug Application (NDA) for the high-dose aspirin product in 2026.
• Potentially conduct a later clinical trial in approximately 32 healthy human volunteers to evaluate the pharmacodynamic effect of high-dose aspirin on platelet inhibition.
• Continue to explore licensing possibilities for the sublingual melatonin sleep-aid product.
• Patent the formulations for sublingually administered melatonin and vitamins D, E, and K.
• Continue development of a sublingual ED (erectile dysfunction) product, with FDA approval likely taking at least 3 years.
• Continue to develop and potentially take to market other sublingual products, including anti-nausea, anti-psychotic, semaglutide, seizure medication, and microdose nicotine.
• Present a plan to regain compliance with Nasdaq's MVLS Rule and Bid Price Rule at a hearing before the Nasdaq Hearings Panel.
• Actively search for a permanent Chief Executive Officer.
• Remediate identified material weaknesses in internal control over financial reporting.
• Raise additional financing through public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, or other marketing/distribution arrangements.

Key Dates

Recommendation

Aspire Biopharma Holdings, Inc. presents an extremely high-risk investment profile. The company is in severe financial distress, evidenced by substantial and increasing net losses, a significant accumulated deficit, and an explicit 'going concern' warning from management and auditors. The imminent threat of Nasdaq delisting due to failure to meet minimum bid price and market value requirements further exacerbates liquidity and investor confidence issues. While there are positive clinical trial results for its sublingual aspirin and new product developments, these are early-stage and do not offset the overwhelming financial and operational challenges. The potential for significant shareholder dilution from ongoing and future capital raises, coupled with a volatile stock price and a history of related-party transactions, makes this a 'strong sell' for any investor seeking capital preservation or growth.

Keywords

Biopharmaceutical, Sublingual Delivery, Aspirin, Nutraceuticals, FDA Approval, Clinical Trials, Nasdaq Delisting, Going Concern, Equity Line of Credit, Convertible Notes, Drug Development, Intellectual Property, Early-stage Company, Healthcare, Pharmaceuticals